Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10661 clinical trials
featured
A Study to Evaluate the Safety Tolerability and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease

Parkinson's Disease (PD). The secondary objective of this study is to evaluate the pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified presence or absence of mutations in the

dyskinesia
  • 266 views
  • 25 May, 2021
  • 14 locations
featured
Study in Parkinson Disease of Exercise

This study is a Phase 3 multi-site, randomized, evaluator-masked, study of endurance treadmill exercise on changes in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at 12 months among persons with early stage Parkinson disease. 370 participants will be randomly assigned to 2 groups: 1)60-65% HRmax …

  • 7 views
  • 04 Jun, 2021
  • 8 locations
featured
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer  

with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective:

her2/neu-negative breast cancer
advanced breast cancer
erbb2
HER2
letrozole
  • 24 views
  • 09 Sep, 2021
  • 4 locations
featured
VAD00001: Respiratory Syncytial Virus (RSV) Study  

Syncytial Virus (RSV) seronegative participants. The secondary objectives of the study are: To quantify the amount of vaccine virus shed by each participant by baseline

  • 51 views
  • 21 Sep, 2021
  • 17 locations
featured
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

This is a Phase 1, multicenter, dose-escalation, open-label study to assess safety, tolerability, preliminary activity, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate-2 or high-risk myelofibrosis.

  • 7 views
  • 18 Jun, 2021
  • 4 locations
featured
ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy. NCT02531516, PCR3003.

primary radiation therapy results in an improvement of metastasis-free survival. The study will include a Screening Phase, Treatment Phase, a Posttreatment Phase, and a Long-term Follow-up Phase. 

  • 57 views
  • 02 Sep, 2021
  • 1 location
featured
  • 0 views
  • 24 Jun, 2021
  • 1 location
featured
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)

This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).

aflibercept
spectral domain optical coherence tomography
macular edema
retinal vein occlusion
  • 0 views
  • 24 Jun, 2021
  • 1 location
featured
AnaLysIs of Both Sex and Device Specific FactoRs on Outcomes in PAtients with Non-Ischemic Cardiomyopathy - Bio Libra

Secondary Objectives All-cause mortality, VT or VF alone, risk of cardiac death, and sudden cardiac death for the total cohort, as well as by sex and by the implanted

sudden cardiac death
ejection fraction
shock
  • 48 views
  • 24 Nov, 2020
  • 1 location
featured
QUILT -2.023: A phase 2, open-label, randomized study of ALT-803 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for patients with metastatic NSCLC

This is a phase 2, open-label, randomized study to compare the safety and efficacy of combination therapy with ALT-803 and pembrolizumab (experimental arm) versus pembrolizumab alone (control arm), as first-line treatment for subjects with metastatic NSCLC in which pembrolizumab is indicated for first-line treatment.

  • 2 views
  • 31 Mar, 2021
  • 1 location